Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delpazolid with Vancomycin in MRSA Bacteremia
NCT05225558Phase 2Terminated
- Sponsor
- LigaChem Biosciences
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of delpazolid in Staphylococcus aureus bacteremia (SAB) (2 arms), sponsored by LigaChem Biosciences. Primary endpoint: Overall Cure Rate at Day 14 (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia). Started Apr 2022; status: terminated.
02
Drugs
delpazolid
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT05225558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225558.